Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-05-24
2011-05-24
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S255050, C514S256000, C514S332000, C514S406000, C514S616000, C544S124000, C544S333000, C544S405000, C546S262000, C548S365100, C564S156000
Reexamination Certificate
active
07947680
ABSTRACT:
The present invention provides adamantyl-diamide derivatives of formula (I):wherein R1and R2are as defined herein, or a pharmaceutically acceptable salt thereof; and pharmaceutical compositions and methods using the same.
REFERENCES:
patent: 3053907 (1962-09-01), Smith et al.
patent: 0897747 (1999-02-01), None
patent: 2003050441 (2003-02-01), None
patent: 0073283 (2000-12-01), None
patent: 03068726 (2003-08-01), None
patent: 2006090244 (2006-08-01), None
Walker, D., et al. 1997. Anxiogenic Effects of High Illumination Levels Assessed with the Acoustic Startle Response in Rats, Biological Psychiatry 42:463-471.
Wheeler-Aceto, H.,et al. 1991. Standardization of the Rat Paw Formalin Test for the Evaluation of Analgesics, Psychopharmacology 104:35-44.
Yan, Q.J., et al. 2005. Suppression of Two Major Fragile X Syndrome Mouse Model Phenotypes by the mGluR5 Antagonist MPEP, Neuropharmacology 49:1053-1066.
Aggleton J.P., et al. 1996. The Effects of Hippocampal Lesions Upon Spatial and Non-Spatial Tests of Working Memory, Behavioral Brain Research 19(2):133-146.
Annett, L.E. 1994. Behavioral Assessment of the Effects of Embryonic Nigral Grafts in Marmosets with Unilateral 6-OHDA Lesions of the Nigrostriatal Pathway, Exp. Neurology 125(2):228-246.
Bach, P., et al. 2007. Metabotropic Glutamete Receptor 5 Modulators and Their Potential Therapeutic Applications, Expert Opinion on Therapeutic Patents 17(4): 371-384.
Berge, S.M., et al. 1977. Pharmaceutical Salts, Journal of Pharmaceutical Science 66(1):2.
Bettayeb, K., et al. 2007. Meriolins, a New Class of Cell Death-Inducing Kinase Inhibitors with Enhanced Selectivity for Cyclin—Dependent Kinases, Chemical Abstracts Service 67(17): 8325-8334.
Bewick, A., et al. 1976. The Electrochemical Difunctionalisation of Saturated Hydrocarbons, Tetrahedron Letters 8:631-364.
Bewick, A., et al. 1977. Electrochemical Difunctionalisation of Adamantane and Further Oxidation of Substituted Adamantanes, Journal of the Chemical Society 16:1831-1834.
Bontempi, B., et al. 1996. Differential Temporal Evolution of Post-Training Changes in Regional Brain Glucose Metabolism Induced by Repeated Spatial Discrimination Training in Mice: Visualization of the Memory Consolidation Process?,European Journal of Neuroscience 8(11);2348-2360.
Breysse, N., et al. 2002. Chronic But Not Acute Treatment with a Metabotropic Glutamate 5 Receptor Antagonist Reverses the Akinetic Deficits in a Rat Model of Parkinsonism, Journal of Neuroscience 22(13):5669-5678.
Buccafusco, J. 2009. Emerging Cognitive Enhancing Drugs, Expert Opinion Emerg. Drugs, 14(4):577-589.
Chen, L., et al. 2009. Chronic, Systemic treatment with a Metabotropic Glutamate Receptor 5 Antagonist in 6-Hydroxydopamine Partially Lesioned Rats Reverses Abnormal Firing of Dopaminergic Neurons, Brain Research, 1286:192-200.
Chemcats Abstract Services, XP002552840, 2010.
Cheng, Y., Pursoff W.H., 1973. Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction, Biochemical Pharmacology 22(23): 3099-3108.
Conn, P.J., et al. 2009. Allosteric Modulators of GPCRS: A Novel Approach for the Treatment of CNS Disorders, Nature Reviews Drug Discovery, 8(1):41-54.
Cryan, J.F., et al. 2000. Antidepressant-Like Behavioral Effects Mediated by 5-Hydroxytryptamine 2C Receptors1, Pharmcol. & Exp. Therap. 295(3):1120-1126.
Cryan, J.F., et al. 2005. Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test, Neuroscience and Biobehavioral Reviews 29:547-569.
David, et.al. 2007. An Animal Model of Altered HPA Axis Responsive to Chronic Antidepressants, SFN meeting in San Diego.
Day, M., 2005. Ovariectomy-induced disruption of long-term synaptic depression in the hippocampal CA1 region in vivo is attenuated with chronic estrogen replacement, Neurobiology of Learning and Memory 83(1):13-21.
Depoortere, R., et al. 2003. SSR181507, A Dopamine D2 Receptor Antagonist and 5-HT1A Receptor Agaonist II: Behavioral Profile Predictive of an Atypical Antipsychotic Activity, Neuropsychopharmacology 28(11):1889-1902.
Dolen G., et al. 2007. Correction of Fragile X Syndrome in Mice, Neuron 56:955-962.
Dulawa, et al. 2004. Effects of Chronic Fluoxetine in Animal Models of Anxiety and Depression, Neuropsychopharmcol. 29:1321-1330.
File, S.E., et al. 2003. A review of 25 years of the social interaction test, European Journal of Pharmacology 463:35-53.
Freed, W.J., et al. 1984. Effects of Neuroleptics on Phencyclidine (PCP)-Induced Locomotor Stimulation in Mice, Neuropharmacology 23(2A):175-181.
Fung, Y.K., et al. 1986. Modulation of Apomorphine-Induced Climbing Behavior by Estradiol, Pharmacology Biochemistry and Behavior 24(1):139-141.
Fung, Y.K., et al. 1987. Inhibition by Bromoestrogens of the Effects of Estradiol on Apomorphine-Induced Climbing Behavior, Steriods 49(4-5):287-294.
Gould, T.J., et al. 2002. MK-801 Disrupts Acquisition of Contextual Fear Conditioning but Enhances Memory Consolidation of Cued Fear Conditioning, Behavioral Pharmacology 13:287-294.
Hamm, A.O., et al. 2003. Affective Blindsight: Intact Fear conditioning to a Visual Cue in a Cortically Blind Patient, Brain 126:267-275.
Holick, et al. 2008. Behavioral Effects of Chronic Fluoxetine in BALB/cJ Mice Do Not Require Adult Hippocampal Neurogenesis or the Serotonin 1A Receptor, Neuropsychopharmcology 33:406-417.
Jaeschke, G., et al. 2008. mGlu5 Receptor Antagonists and Their Therapeutic Potential, Expert Opinion on Therapeutic Patents 18(2): 123-142.
Kim, S.H., et al. 1992. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat, Pain 50:355-363.
Korte, S.M., et al. 2003. A Robust Animal Model of State Anxiety: Fear-Potentiated Behaviour in the Elevated Plus-Maze, European Journal of Pharmacology 463:143-175.
Lee, E. H., et al. 1992. Comparative Studies of the Neurotoxicity of MPTP in Rats of Different Ages, Chinese Journal of Physiology 35(4):317-336.
Liu, H.Y., et al. 2002. Estrogen inhibition of EAE involves effects on dendritic cell function, Journal of Neuroscience Research 70:238-248.
May, L.T., 2007. Allosteric Modulation of G Protein-Coupled Receptors, Annual Review of Pharmacology Toxicolology 47:1-151.
Moore, N. A., et al. 1994. Effects of Olanzapine and Other Antipyschotic Agents on Responding Maintained by a Conflict Schedule, Behavioural Pharmacology 5:196-202.
Morris. 1981. Spatial Localization Does Not Require the Presence of Local Cues, Learning and Motivation 12:239-260.
Muir, J.L., et al. 1995. Reversal of Visual Attentional Dysfunction and Following Lesions of the Cholinergic Basal Forebrain by Physostigmine and Nicotine but not by the 5-HT3 Receptor Antagonist Ondansetron, Pyschopharmacology (Berl) 118(1):82-91.
Njung'E K., et al. 1991. Evaluation of Marble-burying behavior as a Model of Anxiety, Pharmacology, Biochemistry and Behavior 38: 63-67.
O'Brien, J.A., et al. 2003. A Family of Highly Selective Allosteric Modulators of the Metabotropic Glutamate Receptor Subtype 5, Mol Pharmacol 64:731-740.
Overstreet, D.H., et al. 2005. Antidepressant-like Effects of the Vasopressin V1B Receptor Antagonist SSR149415 in the Flinders Sensitive Line Rat, Pharmacology Biochemistry Behavior 82(1):223-227.
Paulekuhn, G.S., et al. 2007. Trends in Active Pharmaceutical Ingredient Salt Selection Based on Analysis of the Orange Book Database, Journal of Medicinal Chemistry 50:6665-6672.
Robbins, et al. 1998. Neural Systems Underlying Arousal and Attention, Annual NY Academy of Science 846:222-237.
Rylander, D., et al. 2009. Pharmacological Modulation of Glutamate Transmission in a Rat Model of L-DOPA-Induced Dyskinesia: Effects on Motor Behavior and Striatel Nuclear Signaling, Journal of Pharmacology and Experimental Therapeutics 330(1):227-235.
Sams-Dodd, F. 1998. Effects of Continuous D-Amphetamine and Phencyclidine Administration on Social Behaviour, Stereotyped Behaviour, and Locomotor Activity in Rats, Neuropharmacology 19(1):18-25.
Santarelli., et al. 2003. Requirement of H
Doller Dario
Grenon Michel
Guo Maojun
Jimenez Hermogenes N.
Li Guiying
Bianchi Kristin
Buck Margaret M.
H. Lundbeck A/S
Kalinchak Stephen G.
Saeed Kamal A
LandOfFree
Adamantyl diamide derivatives and uses of same does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Adamantyl diamide derivatives and uses of same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adamantyl diamide derivatives and uses of same will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2637934